S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$4.08
-0.07 (-1.69 %)
(As of 10/15/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.02
$4.18
50-Day Range
$2.86
$4.62
52-Week Range
$2.43
$5.87
Volume2.25 million shs
Average Volume2.18 million shs
Market Capitalization$404.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
30 days | 90 days | 365 days | Advanced Chart
Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma logo

About Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
77
Year Founded
1992

Sales & Book Value

Annual Sales
$6.91 million
Book Value
($0.53) per share

Profitability

Net Income
$-63.74 million
Net Margins
-856.96%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$404.58 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

838th out of 1,361 stocks

Pharmaceutical Preparations Industry

411th out of 668 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Arbutus Biopharma?

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 2,780,000 shares, a decline of 24.9% from the September 15th total of 3,700,000 shares. Based on an average daily volume of 2,340,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 3.5% of the company's shares are short sold.
View Arbutus Biopharma's Short Interest
.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.02. The biopharmaceutical company earned $2.33 million during the quarter, compared to the consensus estimate of $2.07 million.
View Arbutus Biopharma's earnings history
.

How has Arbutus Biopharma's stock been impacted by COVID-19?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 58.1% and is now trading at $4.08.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ABUS?

4 equities research analysts have issued twelve-month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Arbutus Biopharma's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • William H. Collier, President, Chief Executive Officer & Director
  • David C. Hastings, Chief Financial & Accounting Officer
  • Michael J. Sofia, Chief Scientific Officer
  • Elizabeth Howard, Secretary, Chief Compliance Officer & EVP
  • Michael J. McElhaugh, Chief Business Officer

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $4.08.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $404.58 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63.74 million in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 77 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914 or via email at [email protected].


This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.